- Home
- NRXP vs EQ Comparison
NRXP vs EQ Comparison
Compare NRXP & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | EQ |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 157.4M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NRXP | EQ |
|---|---|---|
| Price | $3.24 | $2.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $38.25 | $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 492.6K |
| Earning Date | 05-14-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,225,000.00 | ★ $41,095,000.00 |
| Revenue This Year | $2,547.84 | N/A |
| Revenue Next Year | $1,591.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $0.76 |
| 52 Week High | $5.06 | $3.54 |
Technical Indicators
Market Signals| Indicator | NRXP | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 40.93 | 45.79 |
| Support Level | $2.88 | $1.68 |
| Resistance Level | $3.33 | $2.61 |
| Average True Range (ATR) | 0.32 | 0.19 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 30.83 | 59.62 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.